All News
Update on low-dose glucocorticoids in SLE
Glucocorticoids (GC) have been the mainstay of treatment in SLE for nearly three quarters of a century. GC induce a range of anti-inflammatory effects, quickly relieve some symptoms and lower mortality in some life-threatening flares. However, they also have multiple side effects that limit the duration of treatment, as well as the dose used. Accordingly, the 2023 EULAR recommendations for SLE set a target dose of ≤5mg/day. Is low dose GC an achievable target?
Read ArticleAchieving drug-free remission in axSpA
A clinical trial in early axial spondyloarthritis (axSpA) demonstrated sustained inactive disease status in over 60% of patients.
Read ArticleChoices in GCA
There are a number of diseases where new biologic and targeted synthetic therapeutic options are coming online, and the temptation will be to consider them all equally. GCA is one of those diseases.
Read ArticleDifficult-to-treat RA: are we any closer to predicting who is at risk?
It is almost four years since EULAR published its definition of difficult-to-treat (D2T) rheumatoid arthritis (RA) (1). This marked a formal recognition of the group of patients who, despite the advances in pharmacological therapy for RA, remain symptomatic.
Read ArticleJanet Pope Janetbirdope ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Janet Pope Janetbirdope ( View Tweet)
Janet Pope Janetbirdope ( View Tweet)
Peter Nash drpnash ( View Tweet)
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Janet Pope Janetbirdope ( View Tweet)
Peter Nash drpnash ( View Tweet)
Links:
Peter Nash drpnash ( View Tweet)